Market Intelligence, Clinical Progress, and High-Purity Reagents for Melanoma, Glioma, and Sarcoma Therapeutic Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for CSPG4 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CSPG4 ECD-Fc Fusion Protein High purity (>95%), Endotoxin controlled. Sequence Verified. HEK293 Expressed (Native Glycosylation). |
View CSPG4 Products |
| Gene Delivery | CSPG4 Promise-ORF / Lentivirus Full-length ORF for stable cell line generation. Essential for cell-based conformation assays. |
View CSPG4 Products |
| Benchmark Ab | Anti-CSPG4 Recombinant Antibody Recombinant positive control derived from clinical benchmark clones. |
View CSPG4 Products |
| Validator | CSPG4 siRNA Set For target knockdown and assay specificity verification. |
View CSPG4 Products |
| Related Target A | GD2 Co-expressed ganglioside target in neuroectodermal tumors; ideal for dual-targeting CAR-T/bispecific strategies. |
View GD2 Products |
| Related Target B | MCAM (CD146) Synergistic melanoma cell adhesion molecule involved in metastasis and vascular invasion. |
View MCAM Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Native Glycosylation & Folding | HEK293 mammalian expression system preserves complex chondroitin sulfate attachment sites and native tertiary structure. |
| Epitope Specificity Mapping | Domain-specific truncated recombinant proteins available for precise mapping (D1, D2, and D3 extracellular domains). |
| Lack of Controls | Sequence-verified clinical benchmark antibodies included for assay standardization. |
| False Positives in Flow Cytometry | Validated siRNA sets and high-titer lentiviral overexpression vectors ensure robust positive/negative cell line controls. |
Live CSPG4 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for CSPG4 (also known as Neuron-Glial Antigen 2 / NG2) therapeutics is intensifying, with major players shifting focus from traditional monoclonal antibodies to advanced modalities such as Antibody-Drug Conjugates (ADCs), Bispecific T-cell Engagers (BiTEs), and CAR-T cell therapies. Because CSPG4 is highly overexpressed on melanoma, triple-negative breast cancer (TNBC), glioblastoma, and pediatric sarcomas—while maintaining restricted expression in normal tissues—it represents an exceptional target for tumor-selective ablation. As first-generation therapies reach the clinic, the next wave of R&D is targeting tumor-associated pericytes and the immunosuppressive tumor microenvironment where CSPG4 plays a critical structural role.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| CAR-T / Cell Therapy | Sorrento Therapeutics, Academic Institutions | Glioblastoma, Melanoma, Pediatric Sarcomas | High-titer Lentivirus for stable target overexpression on target cells to validate CAR-T cytolytic activity. |
| Antibody-Drug Conjugates (ADC) | Biotech Consortia, NCI-backed programs | Triple-Negative Breast Cancer (TNBC), Mesothelioma | Internalization validation assays requiring high-purity, natively glycosylated ECD-Fc proteins to monitor receptor-mediated endocytosis. |
| Bispecific Antibodies (BsAb) | Immunotherapy Pioneers | Solid Tumors, Brain Metastases | Simultaneous binding assays requiring high-purity monomeric CSPG4 and CD3 or other immune-checkpoint proteins. |